News
Hosted on MSN2mon
Natco Pharma shares dive 29% in just 2 days; is it time to enter or there's more pain ahead?Natco Pharma ... to-equity (P/E) ratio of 8.83 against a price-to-book (P/B) value of 2.29. Earnings per share (EPS) stood at 98.90 with a return on equity (RoE) of 25.89. Natco Pharma's business ...
Natco Pharma on Tuesday shared a legal update on the ... The stock has a price-to-equity (P/E) ratio of 7.87 against a price-to-book (P/B) value of 2.04. Earnings per share (EPS) stood at 98. ...
Natco Pharma has decided to price Risdiplam, indicated for the treatment of rare genetic disorder Spinal Muscular Atrophy (SMA), at₹15,900. In an update on the legal proceedings on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback